INVESTING SHOW: How biotech 投資家s can 利益（をあげる） from an ageing 全住民 and the 未来 of 薬／医学

• e-mail

The 豊富な western world’s 全住民 is ageing and 薬／医学 is changing 急速な／放蕩な.

生物工学 lies at the 交差点 of this growing need for healthcare and 治療s that are tailored to 患者s, such as immunotherapy, rather than taking a 伝統的な one size fits all approach.

投資家s’ excitement for this 勇敢に立ち向かう new world saw many biotech 基金 and 信用s 配達する startling 業績／成果 from 2012 to 2016 before the 部門 then 苦しむd a 落ちる, as the last US 選挙 brought worries to the fore.

Things have begun to look up again for biotech over the past year and we are joined on this 投資するing Show by Ailsa Craig, of International 生物工学 信用, to find out more about this and the 部門.

Ailsa explains what 生物工学 is, about the 会社／堅いs operating within the 部門, and what some of the companies that her 信用s 投資するs in do.

She discussed how International 生物工学 信用, which dates 支援する to 1994, 投資するs, from unquoted companies to companies 価値（がある） billions.

Ailsa says that it looks for 高度に innovative, high growth companies with pricing 力／強力にする, but explains how it also 捜し出すs to take some of the 危険 out of such a high 火刑／賭けるs 部門.

International 生物工学 信用 has beaten the market over five years, with a 74.9 per cent return, compared to 65.3 per cent for the biotech and healthcare 部門. It is also unusual in 支払う／賃金ing a （株主への）配当, 現在／一般に 4.4 per cent.

?